Inside Germany’s Medical Cannabis Boom

In late April 2025, Allied participated in two leading industry events in Berlin — the Talman House Cannabis Forum and ICBC Berlin. Together, these gatherings highlighted both the scale of opportunity in Europe’s medical cannabis market and the strategic execution required to meet it.

THE NUMBERS BEHIND THE MOMENTUM

Recent data highlights the velocity of change in Germany:

• 457% Growth in Imports: Germany imported 41 tonnes of medical cannabis in Q1 2025 — nearly 4.6x year-over-year [1]

• €1B+ by 2028: Projections indicate market value in Germany will cross €1 billion by 2028, up from €420 million in 2024 [2]

• €36B+ by 2033 : Estimated size of the European medical cannabis market by 2033, growing at 22% CAGR [3]

Germany’s April 2024 rescheduling of cannabis as a non-narcotic transformed the market landscape. This regulatory shift, combined with expanded patient access and enhanced doctor education programs, has created ideal conditions for sustained growth.

This shift is rippling across the continent — with France, Czech Republic, and others expanding frameworks for medical use.

BERLIN INSIGHTS: ALLIED AT TALMAN HOUSE AND ICBC

Allied was honoured to be one of only four companies selected to present at the Talman House Cannabis Forum in Berlin with over 120 attendees. This invitation-only event convened leading cannabis operators, institutional investors and ecosystem partners to discuss emerging opportunities in the European cannabis sector.

That same week, our team engaged at ICBC Berlin — Europe’s largest medical cannabis conference — with over 5,000 participants from 80+ countries.

Across both events, three messages were clear:

1. Pharmaceutical-grade standards are now the baseline expectation

2. Reliable, consistent supply chains are mission-critical

3. Scalability is essential to meet rising market demand

Looking ahead, the trajectory is clear: Europe’s medical cannabis market is shifting from early adoption to mainstream healthcare integration. The companies positioned to deliver consistent quality, regulatory expertise, and scalable operations will capture disproportionate value as the market expands. These themes align with Allied's strategic pillars.

ALLIED EXECUTING ON MARKET OPPORTUNITY

Allied is now preparing initial shipments for two licensed pharmaceutical clients in Germany, with deliveries scheduled over the coming weeks and months. One shipment is currently in manufacturing via our EU-GMP partner in Portugal, while the second is being prepared for direct export from Colombia. This represents our first direct entry into Germany, Europe’s largest and most regulated medical cannabis market — and a key milestone in Allied’s broader expansion across high-value jurisdictions.

These operational steps reflect our systematic approach to delivering consistent, compliant product at scale — the very capabilities emphasized in Berlin by distributors, regulators, and investors alike.

We’ll continue sharing updates as we execute across Germany, Switzerland, the UK, Australia, among others throughout 2025 and beyond.

If you’re active in the space or want to exchange on the industry, we welcome the opportunity to connect.

Investor Relations : ir@allied.health

Website : https://www.allied.health

Disclaimer and Forward-Looking Statements:

No regulatory authority assumes responsibility for the accuracy or adequacy of this release.

This press release includes certain statements that may be deemed "forward-looking statements" under U.S. and Canadian securities laws. Forward-looking statements relate to Allied Corp.’s anticipated developments, strategic objectives, performance, and market opportunities. These include, but are not limited to, statements regarding Allied’s growth in Colombia, Kelowna, Nevada, and other key locations; intellectual property filings; joint development and manufacturing initiatives; and planned product introductions.

Forward-looking statements can often be identified by terms such as "anticipates," "believes," "expects," "intends," "plans," "will," "may," and similar expressions. These statements are based on current assumptions, projections, and management’s experience, but are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Notable risks include, but are not limited to, regulatory risks associated with the cannabis industry and market changes ; risks related to competition within the cannabis and medical industries; risks related to potential operational and logistical challenges; risks related to market demand; risks related to economic conditions impacting growth and profitability; risks related to potential delays or adverse changes in project locations or expansion plans; as well as other risks.

Though Allied endeavors to identify important factors that may impact actual outcomes, other unknown factors may also cause results to vary. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

[1] International Cannabis Business Conference. (May 2025).

[2] Prohibition Partners. (October 2024).

[3] Market Data Forecast. (June 2024).